New appointment

#Leadership appointment #New appointment #Numab Therapeutics

Dr Rajesh Chopra joins Numab Therapeutics as Chief Scientific Officer

Numab Therapeutics has appointed Dr Rajesh Chopra as Chief Scientific Officer, who brings nearly four decades of experience across oncology, immunology, translational medicine, and drug development.  Dr Chopra joined Numab from Prologue Medicines, where he served as Chief Scientific Officer, and previously was a Venture Partner at… Read More

#News

#BIOCAPTIVA #Cancer research #Cell-free DNA (cfDNA) #Liquid biopsies #New appointment #University of Edinburgh

BIOCAPTIVA Chair appointment to steer global growth 

BIOCAPTIVA, a University of Edinburgh spin-out that develops advanced technologies to extract cell-free DNA (cfDNA) from blood for cancer liquid biopsies, has appointed experienced life sciences executive, Stephane Argivier as Chair to steer its next phase of international growth.   The company’s patented msX platform has the potential to improve the… Read More

#News

Neurones in the brain
#Leadership appointment #MindMaze Therapeutics #Neuroplasticity #Neuroscience #New appointment

MindMaze Therapeutics appoints strategic advisor for US growth

MindMaze Therapeutics has appointed Dr John Krakauer as a strategic advisor to support its next phase of growth in the United States.  “John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery,” said Zach Henderson, CEO of MindMaze Therapeutics. “As… Read More

#News

Claus Sundgreen
#Appointment #Neuroscience #New appointment #NRG Therapeutics

NRG Therapeutics appoints neuroscience leader as CMO

NRG Therapeutics has announced the appointment of Dr Claus Sundgreen as Chief Medical Officer (CMO), effective from 1 August 2026.  A recognised leader in neuroscience drug development with expertise in ALS, Dr Sundgreen brings over 25 years of clinical leadership with experience spanning translational medicine and all… Read More

#News

New appointment
#New appointment #Nucleome Therapeutics

Nucleome appoints Morrow as Chief Scientific Officer

Michelle Morrow has left her position at Avacta to join Nucleome Therapeutics as Chief Scientific Officer (CSO).  Morrow joins Nucleome with two decades of experience in drug discovery and development and executing R&D strategy across biotech and large pharma.   Prior to Avacta, Michelle was SVP, Head of invoX Therapeutics Innovation,… Read More

#Business & Investment #News

Sanofi offices
#New appointment #Sanofi

Merck’s Belén Garijo takes over at Sanofi

Sanofi's Board of Directors has decided not to renew the Paul Hudson’s contract as CEO and to replace him with current Merck CEO Belén Garijo.  They have announced that Olivier Charmeil, Executive Vice President, General Medicines, will assume the role of Interim Chief Executive Officer during the transition.  Garijo has… Read More

#Business & Investment #News #Trending News

Neurons in the brain
#Amyotrophic lateral sclerosis (ALS) #Appointment #Neuroscience #New appointment #NRG Therapeutics

NRG Therapeutics appoints Paul Thompson as CDO

NRG Therapeutics has expanded its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).  In his role at NRG, Thompson will be project lead for NRG5051 which is on track to commence first-in-human studies in early 2026.   NRG5051 is an oral,… Read More

#News

#Domain Therapeutics #GPCRs #New appointment #Oncology

New Domain chief medical officer to advance GPCR pipeline

Domain Therapeutics has announced the appointment of Dr Jean-Marie Cuillerot as Chief Medical Officer (CMO).  Dr Cuillerot brings pharmaceutical and biotech experience, with a track record in leading successful clinical development programmes and regulatory strategy.   Earlier in his career, Dr Cuillerot served as the medical lead at Bristol-Myers Squibb… Read More

#Business & Investment #News

#Appointment #Drug discovery #New appointment

Drug discovery’s senior appointments: Q2 2025

Here, we provide an overview of the c-level moves that have taken place within the industry between April and June 2025. The ABPI has confirmed that Russell Abberley is the latest President-elect. Abberley, Vice President and General Manager of Amgen UK and Ireland, formally took up the Presidency on 13… Read More

#News

#Appointment #Drug discovery #New appointment

Drug discovery’s 2025 senior level appointments

Here we provide an overview of the c-level moves that have taken place within the industry in first two months of the year.  BeiGene has hired global executive Giancarlo Benelli as Senior Vice President and Head of Europe, who leaves a role as Vice President and Head Radioligand Therapy International… Read More

#Business & Investment #News

New appointment
#Appointment #Career #Drug discovery #New appointment

C-level moves within drug discovery and development

We round-up the key senior career moves in the industry over the last few months. Emile Shaffu, Director of Sales, Newcells Biotech: Shaffu has over 20 years of international sales and management experience in the life sciences, most recently as UK Regional Business Manager at Bionano… Read More

#News

#Appointment #Career #Drug discovery #New appointment

Senior level moves within drug discovery

There have been a significant number of changes in c-level positions within the industry over the last two months. Dale Levitzke, Chief Executive Officer, and Curtis Nicholson, Director of Sales for Europe, Middle East, and Africa (EMEA), Sphere Fluidics: Levitzke brings over 25 years’ experience in… Read More

#News

#Appointment #Drug discovery #New appointment

Drug discovery’s latest top-level appointments

The last couple of months has seen a number of changes in senior roles in the drug discovery sector. Bill Dawson, Chair, Medicines Manufacturing Industry Partnership (MMIP): Dawson is Head of Biologics and Devices Manufacturing at GSK and has over 25 years’ experience in the vaccines, biopharma, pharmaceutical and clinical research… Read More

#Business & Investment #News

New appointments
#Appointment #Career #New appointment #Recruitment

The latest c-level appointments in drug discovery

Despite December usually being a slower time for recruitment, there has been a high number of senior moves within the drug discovery sector over the last three months. Shorla Oncology has appointed Rayna Sethi Herman as Chief Commercial Officer. Herman leaves a role as CCO at… Read More

#News

New appointments
#Appointment #Drug discovery #New appointment

Drug discovery’s senior appointments for Q4

Keep up to speed with the sector’s top executive appointments with DDW’s regular recruitment round-up. Kimryn Rathmell  has been chosen as the 17th director of the National Cancer Institute (NCI), bringing her experience as leader of the Department of Medicine at the Vanderbilt University Medical Center… Read More

#News

New appointments
#Appointment #Drug discovery #New appointment

Drug discovery’s latest top-level appointments

It’s not unusual for such a dynamic industry to have regular shake-ups in senior leadership, especially as innovative new technologies create brand new roles. The last couple of months have seen a number of high-profile job moves in drug discovery. Dr Robert Kirby, COO and Dr Edward Stevens, CSO Metrion… Read More

#Business & Investment #News